These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 39215848)

  • 1. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):13-14. PubMed ID: 38212258
    [No Abstract]   [Full Text] [Related]  

  • 3. Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
    Zhuang-Yan A; Syed YY
    Drugs; 2024 Apr; 84(4):441-448. PubMed ID: 38554243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
    Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
    BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LipiFlow for the treatment of dry eye disease.
    Pucker AD; Yim TW; Rueff E; Ngo W; Tichenor AA; Conto JE
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD015448. PubMed ID: 38314898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape.
    Sheppard JD; Nichols KK
    Ophthalmol Ther; 2023 Jun; 12(3):1397-1418. PubMed ID: 36856980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease.
    Venkateswaran N; Bian Y; Gupta PK
    Clin Ophthalmol; 2022; 16():349-355. PubMed ID: 35173413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry Eye Disease: Focus on Prescription Therapy.
    Marshall LL; Hayslett RL
    Sr Care Pharm; 2023 Jun; 38(6):239-251. PubMed ID: 37231571
    [No Abstract]   [Full Text] [Related]  

  • 9. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry Eye Disease: Present Challenges in the Management and Future Trends.
    Al-Saedi Z; Zimmerman A; Bachu RD; Dey S; Shah Z; Baugh R; Boddu SH
    Curr Pharm Des; 2016; 22(28):4470-90. PubMed ID: 27296759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline nasal spray (Tyrvaya) for dry eye disease.
    Med Lett Drugs Ther; 2021 Dec; 63(1639):198-199. PubMed ID: 35100236
    [No Abstract]   [Full Text] [Related]  

  • 13. Varenicline Solution Nasal Spray: A Review in Dry Eye Disease.
    Frampton JE
    Drugs; 2022 Sep; 82(14):1481-1488. PubMed ID: 36197638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
    Shen Lee B; Toyos M; Karpecki P; Schiffbauer J; Sheppard J
    Ophthalmol Ther; 2022 Aug; 11(4):1333-1369. PubMed ID: 35608780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.
    Tian L; Gao Z; Zhu L; Shi X; Zhao S; Gu H; Xu G; Wang L; Dai H; Zhang H; Jin X; Ma K; Xu Y; Ma L; Pei C; Ke B; Krösser S; Zhang Y; Jie Y
    JAMA Ophthalmol; 2023 Apr; 141(4):385-392. PubMed ID: 36929413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application.
    Wong JC; Barak A
    Pharmacy (Basel); 2024 Jan; 12(1):. PubMed ID: 38392926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Controlled Trial Comparing Tearcare
    Ayres BD; Bloomenstein MR; Loh J; Chester T; Saenz B; Echegoyen J; Kannarr SR; Perez VL; Rodriguez TC; Dickerson JE
    Clin Ophthalmol; 2023; 17():3925-3940. PubMed ID: 38143559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
    Sheppard JD; Evans DG; Protzko EE
    Am J Manag Care; 2023 Nov; 29(14 Suppl):S251-S259. PubMed ID: 37930231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.
    Qin G; Chen J; Li L; Zhang Q; Xu L; Yu S; He W; He X; Pazo EE
    Indian J Ophthalmol; 2023 Apr; 71(4):1316-1325. PubMed ID: 37026263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.